[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020009262A - Vectores de parapoxvirus. - Google Patents

Vectores de parapoxvirus.

Info

Publication number
MX2020009262A
MX2020009262A MX2020009262A MX2020009262A MX2020009262A MX 2020009262 A MX2020009262 A MX 2020009262A MX 2020009262 A MX2020009262 A MX 2020009262A MX 2020009262 A MX2020009262 A MX 2020009262A MX 2020009262 A MX2020009262 A MX 2020009262A
Authority
MX
Mexico
Prior art keywords
pcpv
provides
present
diseases
pvpv
Prior art date
Application number
MX2020009262A
Other languages
English (en)
Inventor
Karola Rittner
Christelle Remy
Christine Thioudellet
Original Assignee
Transgene
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene filed Critical Transgene
Publication of MX2020009262A publication Critical patent/MX2020009262A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se encuentra en el campo de la inmunoterapia viral; la invencion proporciona nuevos virus de pseudo viruela vacuna (PCPV), en particular PCPV recombinante, su composicion asi como su uso terapeutico para prevenir o tratar enfermedades, y notablemente, enfermedades proliferativas como canceres y restenosis y enfermedades infecciosas tales como las crónicas; la presente invencion tambien proporciona metodos para generar y amplificar tal un PCPV y un metodo para obtener o estimular y/o reorientar una respuesta inmune usando tal un PCPV; mas especificamente, la invencion proporciona una alternativa a los vectores de viruela aviaria existente tal como MVA (Virus Ankara Modificado) y puede usarse en gran medida para la vacunación terapeutica.
MX2020009262A 2018-03-07 2019-03-07 Vectores de parapoxvirus. MX2020009262A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305237 2018-03-07
EP18306424 2018-10-31
PCT/EP2019/055744 WO2019170820A1 (en) 2018-03-07 2019-03-07 Parapoxvirus vectors

Publications (1)

Publication Number Publication Date
MX2020009262A true MX2020009262A (es) 2021-01-08

Family

ID=65628796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009262A MX2020009262A (es) 2018-03-07 2019-03-07 Vectores de parapoxvirus.

Country Status (10)

Country Link
US (1) US20210000937A1 (es)
EP (1) EP3762020A1 (es)
JP (2) JP2021516957A (es)
CN (1) CN112512560A (es)
AU (1) AU2019229653A1 (es)
BR (1) BR112020018117A2 (es)
CA (1) CA3093093A1 (es)
IL (1) IL277161A (es)
MX (1) MX2020009262A (es)
WO (1) WO2019170820A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021258008A1 (en) * 2020-06-19 2021-12-23 Immunacor Llc Compositions and methods for treating and preventing viral infection
WO2023083951A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12
CN116121207A (zh) * 2023-02-08 2023-05-16 华南农业大学 一种表达猪圆环病毒3型Cap蛋白的重组羊口疮病毒及其制备方法和应用
WO2024178260A2 (en) * 2023-02-22 2024-08-29 Cornell University Systems and methods for heterologous gene expression by poxvirus vectors
CN116897887A (zh) * 2023-07-31 2023-10-20 湖南中医药大学 一种病毒性哮喘动物模型的构建方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
WO1997032029A1 (de) * 1996-02-28 1997-09-04 Bayer Aktiengesellschaft Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
CA2250041A1 (en) 1996-03-29 1997-10-09 University Of Otago Parapoxvirus vectors
EP0954593A1 (en) 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
CA2384814A1 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
CN1296096C (zh) 2001-12-10 2007-01-24 巴法里安诺迪克有限公司 含痘病毒制剂和制备稳定的含有痘病毒组合物的方法
CA2431349A1 (en) * 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
CA2517181C (en) 2003-02-25 2013-07-16 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
DE602004015995D1 (de) 2003-07-21 2008-10-02 Transgene Sa Polypeptid mit verbesserter cytosin-deaminase-aktivität
DK1765370T3 (da) 2004-07-13 2009-11-02 Aicuris Gmbh & Co Kg Parapox-vira i kombination med andre antivirale midler til behandling af HIV/AIDS
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
EP1951865A4 (en) 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
KR101082296B1 (ko) 2006-06-20 2011-11-09 트랜스진 에스.에이. 폭스바이러스 및 폭스바이러스 조성물 제조 방법
MX2009008118A (es) 2007-01-30 2009-10-13 Transgene Sa Polipeptido e2 del virus del papiloma usado para vacunacion.
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
PT103865A (pt) 2007-10-25 2009-05-15 Univ De Coimbra Nano-transportadores de base lipídica para entrega direccionada de vectores virais e processo para a sua produção
RU2503717C2 (ru) 2007-11-19 2014-01-10 Трансжене Са Поксвирусные онколитические векторы
EP2588665B1 (en) 2010-07-01 2019-05-08 Novozymes A/S Bleaching of pulp
JP2013537409A (ja) * 2010-07-20 2013-10-03 ゾエティス・エルエルシー パラポックスウイルスベクター
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
MX378901B (es) 2014-12-01 2025-03-10 Transgene Sa Formulaciones liquidas estables de virus de vacuna.
ES3011733T3 (en) * 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
EP3497209A4 (en) * 2016-08-09 2020-07-29 City of Hope CHEMERICAL POXVIRUS COMPOSITIONS AND THEIR USES

Also Published As

Publication number Publication date
WO2019170820A9 (en) 2020-05-28
WO2019170820A1 (en) 2019-09-12
US20210000937A1 (en) 2021-01-07
CN112512560A (zh) 2021-03-16
JP2024050588A (ja) 2024-04-10
IL277161A (en) 2020-10-29
BR112020018117A2 (pt) 2020-12-22
CA3093093A1 (en) 2019-09-12
EP3762020A1 (en) 2021-01-13
JP2021516957A (ja) 2021-07-15
AU2019229653A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MX2020009262A (es) Vectores de parapoxvirus.
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
MX2018014573A (es) Vacuna contra el virus del zika.
PH12022550767A1 (en) Hbv vaccines and methods treating hbv
MX2023008067A (es) Virus vaccinia atenuados competentes para replicacion con delecion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
EP4523756A3 (en) Immunotherapeutic vaccine and antibody combination therapy
WO2022140364A3 (en) African swine fever (asf) virus vaccines
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
EA201800148A1 (ru) Оспенная вакцина для лечения рака
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
WO2017139570A8 (en) Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
MX2021014771A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
MX2020001856A (es) Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo.
EA201890042A1 (ru) Вакцина против вируса ящура (вя) на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
MX2022000879A (es) Vacuna viral terapeutica.
MX2021007860A (es) Poxvirux deficiente en m2.
MX2018009506A (es) Vacunas contra el cáncer y métodos de tratamiento que las utilizan.
WO2020028719A3 (en) Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer
PH12021550661A1 (en) Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy
MX2017012389A (es) Vacuna del virus de la parotiditis recombinante jeryl lynn2.
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
MX2023000734A (es) Virus vaccinia recombinante.
PH12022550240A1 (en) Genetically engineered oncolytic vaccinia viruses and methods of uses thereof
WO2021019235A3 (en) Hantavirus antigenic composition